Immunomedics, Inc.(NASDAQ:IMMU) reported a unique immuno-oncology agent, ‘(E1)-3s’, that can lead a patient’s T cells to kill cancer cells with the Trop-2 antigen, the cancer marker, which can be improved by integrating with an immune checkpoint inhibitor.
The experts speak
Cynthia L. Sullivan, the CEO and President of Immunomedics, reported that the potent activity demonstrated by (E1)-3s in this preclinical trial and the prevalence of Trop-2 expression in TNBC make it an attractive applicant for T-cell redirected treatment of breast cancer. Integrating immune checkpoint inhibitors with relayed T-cell treatment may show a new shift for the solid cancers management, including breast, and requires further investigation.
Sullivan added that they consider there is a significant requirement for the patient treatments they are advancing, which underline the value creation prospects accessible to Immunomedics’ stockholders through their robust pipeline. Their advancements in TNBC show the positive development they are making on their near-term achievements and the ability of their team to successfully offer on these goals.
Trop-2 is a receptor seen on different solid cancers and the mark of the Immunomedics’ lead antibody-drug conjugate, IMMU-132. In a single-arm Phase II trial, IMMU-132 has shown promising report in subjects with different late-stage metastatic disease, counting TNBC, non-small-cell and small-cell lung, and urothelial cancers. Thrilled by this report, the firm is interested in developing its current, strong pipeline and formulating another treatment modality for the mentioned and other Trop-2-expressing cancers.
At the same time, updating on its COPD plan, InMed Pharmaceuticals, Inc. (OTCMKTS:IMLFF) reported that its R&D program in the use of CBDs for the chronic obstructive pulmonary disease treatment. In this June, the company launched its COPD plan using its bioinformatics analysis tool to know the targets and prospective active compounds that can be helpful for the treatment of COPD.
Dr. Sazzad Hossain, the Chief Scientific Officer of InMed, reported that considering the impact of this certain protein’s part in lung tissue remodeling and fibrosis, the preliminary report is vital and promising for advancing cannabinoid-based treatments for COPD. It is known that cannabinoids show bronchodilatory, anti-inflammatory and immunosuppressive properties and hence cannabinoid-based treatments may offer safer and effective treatment alternatives for COPD.